MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)
Clinical trials for MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) trials appear
Sign up with your email to follow new studies for MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aleeto tested for rare brain disorder
Symptom relief Recruiting nowThis early-stage study tests whether a new drug called Aleeto is safe and tolerable for people with Multiple System Atrophy (MSA), a rare and serious brain disorder. About 20 adults aged 30 to 75 with a specific type of MSA (parkinsonian subtype) who don't respond well to standar…
Matched conditions: MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)
Phase: EARLY_PHASE1 • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated May 01, 2026 20:42 UTC
-
DNA hunt launched for rare brain diseases – no treatment yet
Knowledge-focused Recruiting nowThis study collects blood samples from up to 1,000 adults with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple system atrophy (MSA), or related conditions, plus their family members. Researchers will sequence the DNA to find known and new genetic varia…
Matched conditions: MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:02 UTC